Genterapiforsøg til behandling af X-linked Retinitis Pigmentosa associeret med varianter i RPGR-genet
Fase 3 randomiseret, kontrolleret undersøgelse af AAV5-RPGR til behandling af X-linked Retinitis Pigmentosa associeret med varianter i RPGR-genet
A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Ghent, Belgien, 9000
- UZ Gent
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital For Sick Children
-
-
-
-
-
Glostrup Municipality, Danmark, 2600
- Rigshospitalet Glostrup
-
-
-
-
-
Edinburgh, Det Forenede Kongerige, EH3 9HA
- NHS Lothian
-
Glasgow, Det Forenede Kongerige, G12 0YN
- Gartnavel General Hospital
-
Leeds, Det Forenede Kongerige, LS9 7TF
- St James University Hospital
-
London, Det Forenede Kongerige, EC1V 2PD
- Moorfields Eye Hospital
-
-
-
-
California
-
La Jolla, California, Forenede Stater, 92093 0946
- Shiley Eye Institute Jacobs Retina Center
-
Los Angeles, California, Forenede Stater, 90027
- Childrens Hospital
-
Palo Alto, California, Forenede Stater, 94303
- Stanford Health Care
-
-
Florida
-
Gainesville, Florida, Forenede Stater, 32607
- VitreoRetinal Associates, PA
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital - Center for Celiac Research and Treatment
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48105
- Univ of Michigan Medical Center
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Duke Eye Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- University of Pittsburgh Medical Center (UPMC)
-
-
Texas
-
Bellaire, Texas, Forenede Stater, 77401
- Retina Consultants of Houston
-
-
-
-
-
Paris, Frankrig, 75012
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
-
-
-
-
-
Amsterdam, Holland, 1105AZ
- VUMC Amsterdam
-
Nijmegen, Holland, 6525EX
- Radboudumc
-
-
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Center
-
-
-
-
-
Florence, Italien, 50134
- Azienda Ospedaliero Universitaria Careggi
-
Milan, Italien, 20142
- Ospedale San Paolo
-
Naples, Italien, 80131
- Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli
-
Roma, Italien, 00198
- IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS
-
-
-
-
-
Basel, Schweiz, 4031
- University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical
-
Lausanne, Schweiz, 1004
- Universite de Lausanne, Hopital ophtalmique Jules-Gonin
-
-
-
-
-
Madrid, Spanien, 28040
- Hosp Univ Fund Jimenez Diaz
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Male or female
- 3 years of age or older
- Has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory
Exclusion Criteria:
- Has had ocular surgery within 3 months prior to screening or is anticipated to require ocular surgery within 6 months after the study intervention administration
- Any investigational ocular treatment or any other ocular treatment that could confound the interpretation of the efficacy results or affect participant compliance with the visit schedule
- Has undergone prior retinal surgery involving the macula, macular laser photocoagulation, external-beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Experimental - Immediate Treatment
Intermediate dose. |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
Andre navne:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
|
Andet: Deferred Treatment
Deferred Treatment |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
Andre navne:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
|
Eksperimentel: Experimental Immediate Treatment
Low dose. |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
Andre navne:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline to Week 52 in Vision-guided Mobility Assessment (VMA) as Measured by the Ability of the Participant to Navigate Through a VMA Maze
Tidsramme: From Baseline to 52 Weeks
|
Change from baseline to Week 52 in VMA as measured by the ability of the participant to navigate through a VMA maze. |
From Baseline to 52 Weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in Mean Retinal Sensitivity Within the Central 10 Degrees Excluding Scotoma (Mean Retinal Sensitivity Within the Central 10 Degree Excluding Scotoma in Static Perimetry [MRS10]) in Static Perimetry at Week 52
Tidsramme: From Baseline to Week 52
|
Change from baseline in mean retinal sensitivity within the central 10 degrees excluding scotoma (MRS10) in static perimetry at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change From Baseline in Mean Retinal Sensitivity of Worse-seeing Eye Within the Central 10 Degrees Excluding Scotoma in Static Perimetry (MRS10) at Week 52
Tidsramme: From Baseline to Week 52
|
Change from baseline in mean retinal sensitivity of worse-seeing eye within the central 10 degrees excluding scotoma in static perimetry (MRS10) at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Full Visual Field at Week 52
Tidsramme: From Baseline to Week 52
|
Pointwise response in full visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in Full Visual Field at Week 52
Tidsramme: From Baseline to Week 52
|
Pointwise response in worse-seeing eye in full visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in the Central 30 Degrees Visual Field at Week 52
Tidsramme: From Baseline to Week 52
|
Pointwise response in the central 30 degrees visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in the Central 30 Degrees Visual Field at Week 52
Tidsramme: From Baseline to Week 52
|
Pointwise response in worse-seeing eye in the central 30 degrees visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change From Baseline in Retinal Function as Assessed by Mean Retinal Sensitivity Within the Full Visual Field (MRS90) in Static Perimetry at Week 52
Tidsramme: From Baseline to Week 52
|
Change from baseline in retinal function as assessed by mean retinal sensitivity within the full visual field (MRS90) in static perimetry at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Functional Vision by Using Vision-guided Mobility Assessment (VMA) Response in the "Worse-seeing Eye" at Week 52
Tidsramme: From Baseline to Week 52
|
Change in functional vision by using VMA assessment in the "Worse-seeing Eye" at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52
Tidsramme: From Baseline to Week 52
|
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by Monocular Low Luminance Visual Acuity Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter score at Week 52
Tidsramme: From Baseline to Week 52
|
Change from baseline in visual function as assessed by monocular low luminance visual acuity using the ETDRS chart letter score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by monocular Best Corrected Visual Acuity (BCVA) Using the ETDRS Chart Letter Score at Week 52
Tidsramme: From Baseline to Week 52
|
Change From Baseline in visual function as assessed by monocular BCVA using the ETDRS chart letter score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by Low Luminance Visual Acuity Using the ETDRS Chart Letter Score in Worse-seeing Eye at Week 52
Tidsramme: From Baseline to Week 52
|
Change from baseline in visual function as assessed by low luminance visual acuity using the ETDRS chart letter score in worse-seeing eye at Week 52. |
From Baseline to Week 52
|
|
Number of Participants with Ocular and Non-ocular Adverse Events
Tidsramme: Day 1 - Week 52
|
Number of participants with ocular and non-ocular adverse events will be assessed. |
Day 1 - Week 52
|
|
Number of Participants With Abnormalities in Laboratory Assessments
Tidsramme: Day 1 - 52 Weeks
|
Number of participants with abnormalities in laboratory assessments will be assessed. |
Day 1 - 52 Weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Study Director, MeiraGTx Ocular UK Ltd
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- CR109258
- 2020-002873-88 (EudraCT nummer)
- MGT-RPGR-021 (Anden identifikator: MeiraGTx Ocular UK Ltd)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .